您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2015, Vol. 53 ›› Issue (4): 1-5.doi: 10.6040/j.issn.1671-7554.0.2014.666

• 基础医学 •    下一篇

半乳凝素-9抑制胶质瘤细胞增殖及迁移

姚众1, 陈为亮1, 徐洋洋1, 何影2, 曲迅2, 李新钢1   

  1. 1. 山东大学齐鲁医院神经外科 山东大学脑科学研究所, 山东 济南 250012;
    2. 山东大学齐鲁医院基础医学研究所, 山东 济南 250012
  • 收稿日期:2014-10-08 修回日期:2014-12-23 出版日期:2015-04-10 发布日期:2015-04-10
  • 通讯作者: 李新钢.E-mail:lixg@sdu.edu.cn E-mail:lixg@sdu.edu.cn
  • 基金资助:
    国家自然科学基金(81172404,81372720)

Galectin-9 inhibits proliferation and migration of glioma cells

YAO Zhong1, CHEN Weiliang1, XU Yangyang1, HE Ying2, QU Xun2, LI Xingang1   

  1. 1. Department of Neurosurgery, Qilu Hospital of Shandong University, Brain Science Research Institute, Shandong University, Jinan 250012, Shandong, China;
    2. Institute of Basic Medical Sciences, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Received:2014-10-08 Revised:2014-12-23 Online:2015-04-10 Published:2015-04-10

PDF (PC)

422

摘要： 目的 研究半乳凝素-9(galectin-9)对胶质瘤细胞系U251增殖和迁移能力的影响,并探讨其作用机制.方法 利用实时定量PCR方法检测胶质瘤细胞系中galectin-9的表达情况;加入不同浓度(1、4、8、16 μg/mL)外源galectin-9蛋白处理一定时间(12、24、36 h)后,CCK-8、Transwell实验检测细胞增殖和迁移能力;另外,在galectin-9处理的同时加入其竞争性抑制剂乳糖,观察其对增殖、迁移作用的影响.结果 4种胶质瘤细胞系均极低水平表达galectin-9;8、16 μg/mL 浓度的galectin-9处理组的增殖率较对照组明显降低(P< 0.001),随着时间延长,细胞增殖率逐渐降低(P< 0.01),添加乳糖组细胞增殖率相对于未加乳糖组增高(P< 0.05);外源性galectin-9刺激不同时间,穿至膜下的细胞数较对照组明显减少(P< 0.01),添加乳糖组细胞数较未加乳糖组增多(P< 0.05).结论 半乳凝素-9可明显抑制胶质瘤细胞的增殖,具有浓度和时间依赖性,并且能够有效抑制胶质瘤细胞的迁移.

关键词: 胶质瘤, 迁移, 半乳凝素-9, 增殖

Abstract: Objective To investigate the effects of exogenous galectin-9 on the proliferation and migration of glioma cells and its potential mechanism. Methods The expression of galectin-9 in glioma cells was detected with real-time quantitative polymerase chain reaction (PCR). After glioma cell line U251 was treated with different concentrations of exogenous galectin-9 (1, 4, 8, 16 μg/mL), the changes of proliferation and migration were tested with cell count kit-8 (CCK-8) and transwell chambers respectively at different time (12, 24, 36 h). When the competitive inhibitor lactose was added, the changes in proliferation and migration were detected. Results The expression of galectin-9 in 4 glioma cell lines was low or barely detected. Cells treated with 8 and 16 μg/mL galectin-9 showed decreased cell proliferation rates, compared with control group (P <0.001). With time passing by, the cell proliferation rate decreased gradually (P <0.01). After lactose treatment, cell proliferation rate increased (P <0.05). Galectin-9 treatment significantly reduced the numbers of cells penetrating the micropomus membrane (P <0.01), while lactose treatment increased the number of cells, compared with the untreated group (P<0.05). Conclusion Galectin-9 effectively inhibits proliferation of glioma cells in a time- and dose-dependent manner, and it can also inhibit the migration of glioma cells.

Key words: Proliferation, Migration, Glioma, Galectin-9

中图分类号: 

  • R739.4
[1] Hirashima M, Kashio Y, Nishi N, et al. Galectin-9 in physiological and pathological conditions[J]. Glycoconjugate Journal, 2004, 19(7-9):593-600.
[2] Matsumoto R, Matsumoto H, Seki M, et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes[J]. J Biol Chem, 1998, 273(27):16976-16984.
[3] Kobayashi T, Kuroda J, Ashihara E, et al. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways[J]. Leukemia, 2010, 24(4):843-850.
[4] Nobumoto A, Nagahara K, Oomizu S, et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices[J]. Glycobiology, 2008, 18(9):735-744.
[5] Zhang ZY, Dong JH, Chen YW, et al. Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma[J]. Asian Pacific J Cancer Prev, 2012, 13(6):2503-2509.
[6] 顾长江, 吴寒盛, 陈毅, 等. 半乳凝素9在肝细胞肝癌患者中的表达及其与预后的关系[J]. 中华医学杂志, 2013, 93(26):2025-2028. GU Changjiang, WU Hansheng, CHEN Yi, et al. Expression and prognostic value of galectin-9 in hepatocellular carcinoma patients[J]. National Medical Journal of China, 2013, 93(26):2025-2028.
[7] 郭素平, 马军, 唐芙爱, 等. 食管鳞状细胞癌组织中Galectin-9和MMP-2蛋白的表达及与预后的关系[J]. 郑州大学学报:医学版, 2012, 47(6):749-752. GUO Suping, MA Jun, TANG Fuai, et al. Relationship between prognosis and expressions of Galectin-9 and MMP-2 in esophageal squamous cell carcinoma tissue[J]. Journal of Zhengzhou University: Medical Sciences, 2012, 47(6):749-752.
[8] Lahm H, André S, Hoeflich A, et al. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by PT-PCR and its implications for diagnostic and therapeutic procedures[J]. J Cancer Res Clin Oncol, 2001, 127(6):375-386.
[9] Matsumoto R, Matsumoto H, Seki M, et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes[J]. J Biol Chem, 1998, 273(27):16976-16984.
[10] Jiang J, Jin MS, Kong F, et al. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer[J]. PLoS One, 2013, 8(12):e81799. doi:10.1371/journal.pone.0081799. eCollection 2013.
[11] Steelman AJ, Smith R 3rd, Welsh CJ, et al. Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis[J]. J Biol Chem, 2013, 288(33):23776-23787.
[12] Yoshida H, Imaizumi T, Kumagai M, et al. Interleukin-1beta stimulates galectin-9 expression in human astrocytes[J]. Neuroreport, 2001, 12(17):3755-3758.
[13] Wiersma VR, Bruyn M, Ginkel RJ, et al. The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells[J]. Journal of Investigative Dermatology, 2012, 132(9):2302-2305.
[14] Irie A, Yamauchi A, Kontani K, et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer[J]. Clin Cancer Res, 2005, 11(8):2962-2968.
[15] Miyanishi N, Nishi N, Abe H, et al. Carbohydrate-recognition domains of galectin-9 are involved in intermolecular interaction with galectin-9 itself and other members of the galectin family[J]. Glycobiology, 2007, 17(4):423-432.
[16] Ishikawa A, Imaizumi T, Yoshida H, et al. Double-stranded RNA enhances the expression of galectin-9 in vascular endothelial cells[J]. Immunol Cell Biol, 2004, 82(4):410-414.
[1] 王晓磊 张海涛 张辉 郭成浩. 舒血宁注射液对高碘致培养血管内皮细胞损伤的保护作用[J]. 山东大学学报(医学版), 2209, 47(6): 38-.
[2] 王琳琳 孙美丽 孙玉萍 张楠 刘传勇. 中心体α-微管蛋白、γ-微管蛋白在脑胶质瘤中的表达及其与Survivin表达的相关性研究[J]. 山东大学学报(医学版), 2209, 47(6): 103-.
[3] 李涵,付婷婷,张磊,延冰,孙涛,郭峰,尹晓. 过氧化物酶增殖物激活受体γ激动剂对24例肥胖症患者米色脂肪细胞分化的影响[J]. 山东大学学报 (医学版), 2020, 1(9): 8-13.
[4] 孙薏丰,高玉,梁永媛,高杨. CPLX2在30例肝癌组织的表达及其对体外细胞增殖与侵袭的影响[J]. 山东大学学报 (医学版), 2020, 1(9): 34-39.
[5] 李刚,薛皓,邱伟,赵荣荣. 脑胶质瘤抑制性免疫微环境形成机制及研究进展[J]. 山东大学学报 (医学版), 2020, 1(8): 67-73.
[6] 吴强,何泽鲲,刘琚,崔晓萌,孙双,石伟. 基于机器学习的脑胶质瘤多模态影像分析[J]. 山东大学学报 (医学版), 2020, 1(8): 81-87.
[7] 陈安静,张训. 靶向小类泛素化修饰的胶质瘤治疗新策略[J]. 山东大学学报 (医学版), 2020, 1(8): 88-94.
[8] 江涛. 类脑智能在脑科学的前沿应用[J]. 山东大学学报 (医学版), 2020, 1(8): 10-13.
[9] 付洁琦,张曼,张晓璐,李卉,陈红. Toll样受体4抑制过氧化物酶体增殖物激活受体γ加重血脂蓄积的分子机制[J]. 山东大学学报 (医学版), 2020, 1(7): 24-31.
[10] 马青源,蒲沛东,韩飞,王超,朱洲均,王维山,史晨辉. miR-27b-3p调控SMAD1对骨肉瘤细胞增殖、迁移和侵袭作用的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 32-37.
[11] 李宁,李娟,谢艳,李培龙,王允山,杜鲁涛,王传新. 长链非编码RNA AL109955.1在80例结直肠癌组织中的表达及对细胞增殖与迁移侵袭的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 38-46.
[12] 徐继禧,陈伟健. 髓内弥漫性中线胶质瘤伴H3 K27M突变1例[J]. 山东大学学报 (医学版), 2020, 1(7): 96-101.
[13] 张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 1(7): 7-14.
[14] 王凯民,谭娟娟,严志强,李志强. Sirtuin在低氧诱导人脐带间充质干细胞增殖中的作用[J]. 山东大学学报（医学版）, 2017, 55(7): 23-30.
[15] 史培堃,曾贝妮,吴伟芳,胡晓燕,马天加,周亚滨. Keap1在肾细胞癌中的表达及其作用[J]. 山东大学学报（医学版）, 2017, 55(3): 94-99.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发